Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Dna Scns (NQ: APDN )

1.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.080
Bid (Size) 0.7500 (1)
Ask (Size) 1.490 (3)
Prev. Close 1.080
Today's Range 1.080 - 1.080
52wk Range 0.7500 - 1.925
Shares Outstanding 13,687,420
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023
APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Applied DNA Sciences: Q4 Earnings Insights
Via Benzinga

Performance

YTD
-31.21%
-31.21%
1 Month
+12.50%
+12.50%
3 Month
-16.92%
-16.92%
6 Month
-28.00%
-28.00%
1 Year
-25.52%
-25.52%

More News

Read More
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Earnings Scheduled For December 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
Via ACCESSWIRE
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
Via ACCESSWIRE
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Via ACCESSWIRE
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Via ACCESSWIRE
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Via ACCESSWIRE
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Via ACCESSWIRE
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
Via ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Earnings Preview: Applied DNA Sciences
Via Benzinga
Applied DNA Sciences: Q2 Earnings Insights
Via Benzinga
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
Via ACCESSWIRE
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
Via ACCESSWIRE
3 Penny Stocks to Buy Before the Breakout
Via InvestorPlace
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
Via ACCESSWIRE
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
Via ACCESSWIRE
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
From Applied DNA Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.